Zacks Investment Research upgraded shares of ADVISORY BOARD (ABCO) from NEUTRAL to OUTPERFORM on July 10, 2012, with a target price of $52.90.
The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides its best practices research and analysis through discrete annual programs to a membership of more than 2,000 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program provides members with best practices research reports, executive education and other supporting research services.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ADVISORY BOARD (ABCO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment